Pediatric Tuberculosis

Size: px
Start display at page:

Download "Pediatric Tuberculosis"

Transcription

1 Pediatric Tuberculosis Rafael Hernandez, MD PhD Attending Physician, Instructor Pediatric Infectious Diseases Disclosures No financial conflicts Off-label use: Drugs used in typical HZRE regimens are approved for use in children Particular combinations or antibiotics used in drug-resistanttb resistant (eg. Fluoroquinolones) may be off label (not approved for TB or not approved in children), but I will only focus on uses consistent with national and international guidelines Risk of Complacence Towards Childhood TB Uncommon: 485 cases in children < 15yo in U.S. (CDC 2013) Typically contagious risk is lower than adult cases Paucibacillary disease is common often smear negative Diagnosis is difficult Cultures often difficult to obtain and lower yield More reliance on clinical diagnosis BUT. 1

2 Large Global Burden of Pediatric TB Approx 550,000 new cases in 2013 (<15yo) Estimated 20-40% of cases in high burden nations are children under age 15 yo Indirect impact >9 million orphans worldwide from TB Loss of family income if parent diagnosed (average 60%) AND (WHO 2014, Swaminathan and Rekha 2010) Additional reasons for concern Young children are at increased risk for severe or disseminated disease (meningitis, miliary TB) Sentinel public health event Likely recent/ongoing transmission Limited circle of contacts Identify infectious cases in community Objectives for Lecture Review epidemiology of childhood TB Understand latent TB screening in children Understand treatment of latent TB in children Compare/contrast children vs. adults: Presentation of active TB disease Diagnosis of active TB disease Develop treatment regimens for active TB in children 2

3 Three Basic Clinical Scenarios Screening in healthy children Screening/evaluation of contacts to contagious TB cases Evaluation and treatment of symptomatic children Natural History of Pediatric TB Hypersensitivity Occult Bacteremia Incubation Milary TB TBM Segmental lesion Pleural dz Osteo-articular dz Adult-type dz Reactivation Marais, et al 2004 Based on Wallgreen, 1948 Risk of Disease Correlates with Age No clear association between age and initial infection w/tb BUT Highest progression to active disease in infants (<1 yo): Disease risk 30-50% TB Meningitis or miliary disease in 10-20% Mortality risk 5-10% in infants < 1 yo Lowest risk in 5-10 yo Overall 2%, <0.5% disseminated Older children develop adult like disease Marais, et al

4 Transmission Generally airborne droplet route (<10 um) Smear positive status is most effective marker of infectiousness Most childhood TB is smear negative, with lower bacterial burdens (less than 15% smear positive) Series at Texas Children s Hosp 7 of 59 children potentially infectious (5 smear positive) 15% of family caregivers have undiagnosed TB Auramine- O Cruz, et al For once children are not the vectors of disease!!! To understand the epidemiology of childhood TB, you need to understand the epidemiology of adult TB in your community Targeted TB Screening in US Screen all children with HIV or other risk for TB progression (transplant, anti-tnf agents, high-dose steroids...) Screen asymptomatic children in the US w/ risk questionnaire Should be done at 2 wk, 6 mo, 12 mo, annual WCCs Has a family member or contact had TB disease? Has a family member had a positive tuberculin skin test result? Was your child born in a high-risk country? (countries other than the U.S., Canada, Australia, New Zealand, or Western/Northern Europe) Has your child traveled (had contact with resident populations) to a high-risk country for more than 1 week? Consider asking about close contact with other high risk populations (homeless, prison, HIV + persons, foreign visitors) THESE QUESTIONS REFLECT EPIDIMEOLOGY Test children responding YES (with a NEW risk) Based on AAP RedBook 4

5 Epidemiology in King County 5.8 per 100K (2013) vs. 2.7 WA State Majority of cases foreign born (84%) 17% of cases resistant to 1 drug Childhood TB (2012): 9 cases in <15 yo, 5 cases in <5 yo At Seattle Children s almost all cases foreign born or with foreign born household contact Epidemiology in United States Observational x-sectional study at 20 U.S. sites (Pang, et al. Pediatrics 2014 cases in children < 5yo) 83% of Cases in US Born Children (vs. adults) Estimated TB Rates per 100K children: 2.57 All Children Foreign-born children 4.81 US born with 1 foreign born parent 0.75 US born, with US born parents Source cases most often in home/family Pang, et al

6 AAP RedBook 2015 IGRA vs. TST Some experts believe IGRA ok in 2-4 yo Reminder: TB antigens in IGRA are not present in BCG vaccine or common NTM pathogens Interpretation of TST? Similar to adults 5 mm or greater AAP RedBook Close contact with known or suspected contagious people with tuberculosis disease Suspected to have tuberculosis disease: Findings on chest radiograph consistent t with active or previous tuberculosis disease Clinical evidence of tuberculosis disease (exam or lab) Children receiving immunosuppressive therapy (corticosteroids, anti-tnf agents) or with immunosuppressive conditions, including HIV infection Interpretation of TST? (cont.) 10 mm or greater Children at increased risk of disseminated TB disease: Children younger than 4 years of age Children with other medical conditions, including Hodgkin disease, lymphoma, diabetes mellitus, chronic renal failure, or malnutrition Children with likelihood of increased exposure to TB disease: Children born in high-prevalence regions of the world Children who travel to high-prevalence regions of the world Children frequently exposed to adults who are HIV infected, homeless, users of illicit drugs, residents of nursing homes, incarcerated or institutionalized 15 mm or greater Children 4 years without any risk factors (Generally do not need testing but sometimes required by schools, volunteer positions, etc.) 6

7 Live virus vaccine in prior 4-6 weeks is contraindication to TST (and IGRA) MMR vaccine known to blunt response to PPD (assume similar effect on IGRAs) Give at same time as TST OR WAIT 4-6 weeks post vaccine No data for other live viral vaccines (Varicella, Influenza, Yellow Fever) general rec is wait 4-6 weeks No evidence that inactivated/subunit vaccines affect TST BCG Vaccination Live Attenuated strain of M. bovis Widely used at birth (>100 countries) Estimated 80% protective against meningitis and miliary TB in children, less effective against pulmonary disease May cross-react with TST (not IGRA) BCG recommendations in US: HIV-negative, non-immunosupressed AND Continuously exposed to INH and RIF-resistant TB OR Continuously exposed to contagious TB and cannot be given anti-tb drugs Should prior receipt of BCG vaccine affect your interpretation of TST? GENERALLY NO But multiple factors affect how individuals who received BCG react to TST and subsequent clinical action: Age at receipt of BCG Time since receiving i BCG Number of doses of BCG Strain of BCG given Symptoms consistent with TB disease Known exposure (more likely to represent TB infection) CXR findings consistent with current or past disease General Rule: TEST ONLY IF YOU WOULD TREAT POSITIVES 7

8 How should a patient with a positive TST or IGRA be treated? Determine Latent TB Infection (LTBI) vs. TB Disease Focused History & Physical: Cough > 2 weeks w/o improvement Fever > 1 week/night sweats Neurologic symptoms (fatigue, persistent irritability) Weight loss OR Failure to thrive (Review growth charts!) Symptoms in family/contacts Physical Exam: Lung findings- uncommon (rales, wheeze from nodes compressing airway) Neurologic- alertness, behavior, meningeal signs Check lymph nodes and musculoskeletal symptoms Screening chest X-ray If asymptomatic and CXR w/o evidence of active TB: LTBI All children with positive TST/IGRA should be considered for treatment Antibiotic regimens for LTBI in Children Isoniazid (10 mg/kg, max 300) 1x daily x 9 mo Pyridoxine supplementation recommended for: exclusively breastfed infants, malnourished children, diets poor in pyridoxine, & HIV+ children to reduce neuropathy Hepatotoxicity rare in children Rifampin (10-20 mg/kg, max 600) daily x 6 mo Use if concern for INH resistance or INH intolerance INH+Rifapentine weekly x 12 wk (DOT) Use when concern for compliance Data for >2 yo, HIV negative children/adolescents (Villarino, et al. 2015) (Non-inferior to daily INH) INH 15 mg/kg weekly Rifapentine 10-14kg=300mg, kg=450mg, kg=600mg, kg=750mg, >50kg=900mg Algorithm for contact evaluation of child <5 yo Key differences: More complete evaluation than immunocompetent adult: Perform exam & CXR If less than 8 weeks from last contact initiate window therapy with INH in well children. Neonates are a special case, contact expert From CDC Guidelines

9 Window Therapy Young Children (<5yo) are AT RISK for DISSEMINATED and/or SEVERE DISEASE Start Latent TB treatment after 1 st TST Repeat in 8-10 weeks after last contact with contagious case If negative can stop INH Screening & LTBI Key points: Screening- may use TST or IGRA (but less data for IGRA in <5 yo) Young children are at increased risk: Use lower 10 mm cut off for TST (<4 yo) If exposed- perform complete evaluation, window therapy is recommended (<5 yo) Regimens for LTBI treatment are similar to adults (weight based dosing) Case: 18 mo girl rash, fever, cough 2.5 wk daily fevers, Tmax At onset, clinical dx of pharyngitis- 5d azithro, no improvement 2 wk ago nodules on bilateral shins wk prior developed d cough - Rx: Albuterol, l w/o improvement Sent to ED for evaluation, with elevated inflammatory markers FH/SH: Paternal GF- Visiting from Nigeria x 6 wks, had stomach illness. Pt is US born to Nigerian parents. 9

10 CXR Specimens for Culture Expectorated sputum Induced sputum can be done in young children with RT expertise Gastric aspirate (preferred if sputum not possible) young children, collected in AM after NPO Video instructions from Curry Center Website: ucsf edu/products/pediatric-tuberculosis-tuberculosis guide-gastric-aspirate-procedure Tissue (Lymph node, bone, synovial fluid, pleura) CSF (if any neuro concerns and should be strongly considered in all children less than 1 yo undergoing TB w/u) RELATIVES/CONTACTS Algorithm for Diagnosis (preadolescent children) Normal Positive TST/IGRA Clinical and CXR Evaluation TB symptoms or close contact IGRA/TST (negative result not useful) Abnormal Treat for LTBI as indicated Consistent with TB More consistent with another Dx Other Dx conformed or inconsistent with TB Collect cultures Start 4 Drug Therapy No Very stable condition? Yes Reassess at least weekly Response to non-tb therapy? Other signs/sx Consider TB cultures Work-up /treat other Dx Avoid INH or FQs 10

11 Assess for Extrapulmonary Tuberculosis TB Meningitis meningitis not responding to antibiotics, with a subacute onset, communicating hydrocephalus, stroke, and/or elevated intracranial pressure TB Adenitis painless, fixed, enlarged lymph nodes, especially in the cervical region, with or without fistula formation (may also be Non-TB mycobacteria) Pleural TB Pericardial TB Abdominal TB TB of joints Vertebral TB Skin Renal Eye Decision to treat Most childhood TB is SMEAR Negative in young children Culture yield is likely only 30-60% Diagnosis made on combination of clinical suspicion, possible contacts, TST/IGRA (only positive is helpful), ruling out other likely diagnosis, and response to treatment If you have high clinical suspicion TREAT! You will end up treating some children for TB who in fact have another diagnosis Obtain baseline labs/hiv testing Dosing: First Line Drugs Drug Dose and Range (mg/kg/day) Maximum Daily Dose Formulation (Not all inclusive) Isoniazid 10 (10-15) 300 mg Tabs: 100 mg, 300 mg Syrup: 10 mg/ml * Rifampin 15 (10-20) 600 mg Caps: 150 mg, 300 mg May be compounded Pyrazinamide CDC: WHO: Ethambutol CDC: 15 (15-20) WHO: 20 (15-25) 2000 mg NA 1600 mg NA Tabs: 500 Tabs: 100mg, 400 mg General note: 10% above or below range is acceptable Intermittent dosing (2-3 x weekly) is possible in continuation phase but there is less evidence than in adults to support practice see CDC/WHO guidelines Regimens for Extrapulmonary TB: are the same, but some experts recommend aminoglycoside or ethionamide in place of EMB for meningitis *contains sorbitol- risk of GI upset/diarrhea 11

12 Important follow-up Provide DOT if available Assess compliance (multiple daily medications can be hard, especially in a toddler) Are sign/symptoms improving? Monitor for side effects, include family education? DO MEDS NEED ADJUSTMENT FOR WEIGHT? Assessment of response/duration of treatment: Typical duration 6-9 months Follow-up cultures difficult: use CXR (2 mo will not be normal, should not be worse) and clinical symptoms 12 months for osteo-articular disease or meningitis First Line Drugs: Adverse Effects Drug Adverse Effects Monitoring Isoniazid Hepatotoxicity Rash Peripheral neuropathy Psychosis Rifampin Orange body fluids Advise parents! Hyperbilirubinemia Hepatotoxiticy Pyrazinamide Hepatotoxicity Arthralgia Rash Jaundice Liver enzymes PRN Clinical observation, symptoms Consider need for B6, symptoms Jaundice Liver enzymes PRN Clinical observation Clinical observation Ethambutol Optic neuritis Visual exam if able (but rare in children) Usually baseline labs are drawn, but subsequent labs are only checked if symptoms, other hepatotoxic drugs, or other baseline conditions (such as liver disease) Consider Possibility of MDR-TB WHO estimates prevalence of MDR- TB is the same in adults and children 12

13 Regimens for MDR-TB Similar to Adults CONSULT AN EXPERT! Principals the same as adults GOAL: AT LEAST 4-5 Active Drugs (WHO recommends 6 drugs) Consider drug resistance of Region, Patient and Contact Group 1: Use all first line drugs to which isolate is susceptible INH, RIF, PZA, EMB Group 2 Add one fluoroquinolone Ofloxacin mg/kg/day Max 800 mg Levofloxacin mg/kg/day Max 1 g Moxifloxacin mg/kg/day Max 400 mg Group 3 Add one injectable (for at least 6 months) Amikacin mg/kg/day Max 1 mg Kanamycin mg/kg/day Max 1 mg Capreomycin mg/kg/day Max 1 mg Streptomycin (resistance a mg/kg/day Max 1 mg concern) Regimens for MDR-TB Similar to Adults KEEP ADDING to get to minimum of 4-6 active drugs Group 4 Additional 2 nd Line Drugs (use as many as needed) Cycloserine mg/kg in 2 Max 1 g per day divided doses Ethionamide mg/kg in 2-3 Max 1 g per day divided doses Para-aminosalicyclic aminosalicyclic acid mg/kg in Max 10 g per day (PAS) 2-4 divided doses Group 5 Limited clinical data (use with caution if additional agents needed) Linezolid Amoxicillinclavulanate Imipenem-cilastin Clofazimine Clarithromycin NEW AGENTS: (No dosing info in children) Bedaquiline Delamanid Take Home Points Active TB Disease Children often culture NEGATIVE Complete work-up whenever there is high suscpicion: Collect best specimens possible (Admit) Identify a source case if possible Positive IGRA/TST are useful in diagnosis Risk for disseminated disease is HIGH vs. adults in children under 5 Children tolerate meds well, principles of therapy are similar to adults 13

14 For 18 mo GIRL with 2.5 wks fever: Eventually 1 of 3 gastric aspirates grew: M tuberculosis complex Susceptible to all 1 st line drugs Fever resolved, clinically much improved Source not identified TB during pregnancy/breastfeeding Can treat LTBI during pregnancy (OK to wait until end of 1 st trimester) But possible increase in hepatotoxicity peripartum period Add Pyridoxine (B6) supplement to all pregnant/breast feeding patients TB disease should be treated during pregnancy Use: INH/RIF/EMB for 9 mo (2HRE+7HR) PZA avoided in US due to lack of data, but used by WHO Avoid streptomycin or injectables Congenital tuberculosis is rare, but consider evaluation Post-partum exposure is greater concern for infant Separate Mom and infant if Mom is still infectious Consider whether infant needs INH (once infant disease is ruled out) If Mom has new diagnosis, evaluate the household members! What are other radiographic appearances of TB in children? 14

15 Childhood TB - Various X ray Presentations: Adult type pulmonary disease 15 yo boy AAP RedBook 2012 CXR Nonspecific, intra-observer variation Features suggesting TB: Hilar lymphadenopathy Bronchial compression Chronic consolidation Calcification Miliary pattern Cavity or Lesion in upper lobe(s) is less common in children Zar, H. University of Cape Town 2009 Hilar lymphadenopathy Smith Curr Probl Pediatr 2001; 31:

16 Hilar lymphadenopathy Smith Curr Probl Pediatr 2001; 31: 5- Paratracheal lymphadenopathy Zar, H. University of Cape Town, 2009 Childhood TB - Various X ray Presentations: Miliary tuberculosis AAP RedBook

17 Childhood TB - Various X ray Presentations: Preschool aged child, showing infiltrate and atelectasis AAP RedBook 2012 Other Diagnostic Testing Xpert on non-sputum and sputum samples More sensitive than smear But less sensitive vs. culture Developing technologies Transcriptional profiling Still not as sensitive as culture Use of Xpert for Diagnosis in Children 17

18 Diagnostic Performance of the Risk Score in the Discovery and Validation Cohorts and as Compared with the IGRA and the Xpert MTB/RIF Assay in the Validation Cohort. Anderson ST et al. N Engl J Med 2014;370: Key Resources AAP Red Book: Red Book 2015: Guidance for national tuberculosis programmes on the management of tuberculosis in children 2nd ed. CDC, ATS and IDSA Guidelines, e_guidelines/ Call: Seattle Children s ID Service Or your local children s hospital 18

Pediatric Tuberculosis

Pediatric Tuberculosis Pediatric Tuberculosis Rafael E. Hernandez, MD PhD Attending Physician, Instructor Pediatric Infectious Diseases Seattle Children s Hospital & University of Washington Disclosures No financial conflicts

More information

Pediatric Tuberculosis

Pediatric Tuberculosis Pediatric Tuberculosis Rafael E. Hernandez, MD PhD Attending Physician, Instructor Pediatric Infectious Diseases Seattle Children s Hospital & University of Washington Disclosures No financial conflicts

More information

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant

More information

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures

More information

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.

More information

Contact Investigation and Prevention in the USA

Contact Investigation and Prevention in the USA Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis

More information

TB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012

TB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012 TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012 Kim Connelly Smith, MD, MPH has the following disclosures to make: No conflict of interests

More information

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009 TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages

More information

Tuberculosis Intensive

Tuberculosis Intensive Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant

More information

Diagnosis and Medical Management of Latent TB Infection

Diagnosis and Medical Management of Latent TB Infection Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,

More information

Management of Pediatric Tuberculosis in New Jersey

Management of Pediatric Tuberculosis in New Jersey Management of Pediatric Tuberculosis in New Jersey Helen Aguila, MD NJMS Global TB Institute December 15, 2011 This presentation is in part adapted from Pediatric Tuberculosis by Ann Loeffler, MD : Francis

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

TB Intensive San Antonio, Texas August 7-10, 2012

TB Intensive San Antonio, Texas August 7-10, 2012 TB Intensive San Antonio, Texas August 7-10, 2012 An Introduction to Childhood Tuberculosis Kim Smith, MD, MPH August 10, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests

More information

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

has the following disclosures to make:

has the following disclosures to make: CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash

More information

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015 Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014 What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks

More information

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict

More information

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

Tuberculosis: A Provider s Guide to

Tuberculosis: A Provider s Guide to Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency

More information

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant

More information

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016 Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

PEDIATRIC TUBERCULOSIS

PEDIATRIC TUBERCULOSIS PEDIATRIC TUBERCULOSIS Ann M. Loeffler, M.D. Faculty Consultant Curry International Tuberculosis Center Objectives At the end of this session, participants will be able to describe: how pediatric patients

More information

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No

More information

Chapter 5 Treatment for Latent Tuberculosis Infection

Chapter 5 Treatment for Latent Tuberculosis Infection Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI

More information

PEDIATRIC TUBERCULOSIS. Objectives. Children are not just small adults. Pediatric Tuberculosis 1

PEDIATRIC TUBERCULOSIS. Objectives. Children are not just small adults. Pediatric Tuberculosis 1 PEDIATRIC TUBERCULOSIS Ann M. Loeffler, M.D. Faculty Consultant Curry International Tuberculosis Center Objectives At the end of this session, participants will be able to describe: how pediatric patients

More information

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea

More information

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Managing Complex TB Cases Diana M. Nilsen, MD, RN Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private

More information

Tuberculosis: update 2013

Tuberculosis: update 2013 Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference

More information

Pediatric TB Theresa Barton, MD

Pediatric TB Theresa Barton, MD TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Pediatric TB Theresa Barton, MD December 9, 2009 Pediatric Tuberculosis Tess Barton, MD Assistant Professor of Pediatrics UT Southwestern

More information

TB Intensive Houston, Texas October 15-17, 2013

TB Intensive Houston, Texas October 15-17, 2013 TB Intensive Houston, Texas October 15-17, 2013 Tuberculosis in Children Kim Connelly Smith, MD, MPH October 16, 2013 Kim Connelly Smith, MD, MPH has the following disclosures to make: No conflict of interests

More information

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:

More information

Disclosures. Current Issues and Controversies in Child and Adolescent Tuberculosis 02/24/2016. NSTC 2016 Annual Meeting

Disclosures. Current Issues and Controversies in Child and Adolescent Tuberculosis 02/24/2016. NSTC 2016 Annual Meeting Current Issues and Controversies in Child and Adolescent Tuberculosis Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea Cruz, M.D.] Disclosures Dr.

More information

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015 Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian

More information

Pediatric TB Intensive Houston, Texas

Pediatric TB Intensive Houston, Texas Pediatric TB Intensive Houston, Texas November 13, 2009 Treatment of Pediatric TB Jeffrey R. Starke, M.D. November 13, 2009 MANAGEMENT OF CHILDHOOD TUBERCULOSIS Jeffrey R. Starke, M.D. Professor of Pediatrics

More information

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017 Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Gary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!!

Gary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!! Gary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!! DECLARATION No relevant conflicts of interest to declare OVERVIEW Burden of disease & epidemiology Pathogenesis (not

More information

Pediatric Tuberculosis: The Essentials October 8, 2014

Pediatric Tuberculosis: The Essentials October 8, 2014 Pediatric Tuberculosis: The Essentials Ann M Loeffler, MD Randall Children s Hospital at Legacy Emanuel Portland, Oregon Curry International TB Center Disclosures Nothing to disclose Learning Objectives

More information

TB in the Patient with HIV

TB in the Patient with HIV TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to

More information

Jeffrey R. Starke, M.D. has the following disclosures to make:

Jeffrey R. Starke, M.D. has the following disclosures to make: AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR

More information

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case

More information

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female % San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7

More information

HIV prevalance in TB cases

HIV prevalance in TB cases TUBERCULOSIS HIV prevalance in TB cases Top 5 AIDS indicative diseases; EUR, 2003 58% 35% 25% 11% 7% TB HIV wasting s. Candidiasis Rec. pneumonia HIV encephal. 26% 25% 31% 31% 16% 8% 7% 16% 14% 10% TB

More information

Diagnosis of tuberculosis in children

Diagnosis of tuberculosis in children Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence

More information

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children

More information

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013 What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2013 Case 1: 52 y/o male Born in the Pacific Islands; some travel in

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

Tuberculosis (TB) Fundamentals for School Nurses

Tuberculosis (TB) Fundamentals for School Nurses Tuberculosis (TB) Fundamentals for School Nurses June 9, 2015 Kristin Gall, RN, MSN/Pat Infield, RN-TB Program Manager Marsha Carlson, RN, BSN Two Rivers Public Health Department Nebraska Department of

More information

Pediatric Tuberculosis

Pediatric Tuberculosis Pediatric Tuberculosis Kim Connelly Smith, MD, MPH April 7, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Kim Connelly Smith, MD, MPH has the following disclosures to

More information

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention

More information

Latent TB Infection (LTBI) Strategies for Detection and Management

Latent TB Infection (LTBI) Strategies for Detection and Management Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu

More information

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey

More information

INDEX CASE INFORMATION

INDEX CASE INFORMATION Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.

More information

Errors in Dx and Rx of TB

Errors in Dx and Rx of TB Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a

More information

TB in Children. Rene De Gama Block 10 Lectures 2012

TB in Children. Rene De Gama Block 10 Lectures 2012 TB in Children Rene De Gama Block 10 Lectures 2012 Contents Epidemiology Transmission and pathogenesis Diagnosis of TB TB and HIV Management Epidemiology The year 2000 8.3 million new TB cases diagnosed

More information

3/25/2012. numerous micro-organismsorganisms

3/25/2012. numerous micro-organismsorganisms Congenital & Neonatal TB A Case of Tuberculosis Congenital or Acquired? Felicia Dworkin, MD NYC DOHMH Bureau TB Control World TB Day March 23, 2012 Congenital TB: acquired by the fetus during pregnancy

More information

At the end of this session, participants will be able to:

At the end of this session, participants will be able to: Advanced Concepts in Pediatric Tuberculosis: Infection Control, Source Case and Contact Investigation Ana M. Alvarez, M.D. Associate Professor Division of Pediatric Infectious Diseases and Immunology University

More information

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.

More information

Pediatric TB Intensive Houston, Texas October 14, 2013

Pediatric TB Intensive Houston, Texas October 14, 2013 Pediatric TB Intensive Houston, Texas October 14, 2013 Diagnosis and Management of Tuberculosis in Adolescents Andrea T. Cruz, MD, MPH Sections of Infectious Diseases & Emergency Medicine October 14, 2013

More information

TB Intensive San Antonio, Texas May 7-10, 2013

TB Intensive San Antonio, Texas May 7-10, 2013 TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection? Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:

More information

Pediatric TB Radiology: It s Not Black and White Part 2

Pediatric TB Radiology: It s Not Black and White Part 2 Experiencing technical difficulties? Please call Adobe Connect for technical assistance at 1-800-422-3623 Pediatric TB Radiology: It s Not Black and White Part 2 June 18, 2018 A National Webinar June 18,

More information

European Respiratory Society Congress Barcelona President Award. Dr Walther Guerrero Ciquero

European Respiratory Society Congress Barcelona President Award. Dr Walther Guerrero Ciquero TUBERCULOSIS Homework European Respiratory Society Congress Barcelona 2010 President Award Dr Walther Guerrero Ciquero ERS will continue to honour his memory through a Fellowship bearing his name. Stop

More information

TB in the Correctional Setting Florence, Arizona October 7, 2014

TB in the Correctional Setting Florence, Arizona October 7, 2014 TB in the Correctional Setting Florence, Arizona October 7, 2014 Diagnosis and Treatment of TB Disease Renuka Khurana, MBBS, MPH October 7, 2014 Renuka Khurana, MSSB, MPH has the following disclosures

More information

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

TUBERCULOSIS. Presented By: Public Health Madison & Dane County TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any

More information

CHAPTER 3: DEFINITION OF TERMS

CHAPTER 3: DEFINITION OF TERMS CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria

More information

TUBERCULOSIS. Pathogenesis and Transmission

TUBERCULOSIS. Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are

More information

At the end of this session, participants will be able to:

At the end of this session, participants will be able to: Advanced Concepts in Pediatric TB: Treatment of Tuberculosis Disease Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [with help from Andrea Cruz, M.D.] Objectives At the end

More information

Ian Kitai TB Specialist. Division of Infectious Diseases Sickkids

Ian Kitai TB Specialist. Division of Infectious Diseases Sickkids Ian Kitai TB Specialist Division of Infectious Diseases Sickkids Review Clinical presentation of TB disease childhood How to assess risk for TB infection How to assess risk for disease if infected TST

More information

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254) Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)-750-5496 Local health care providers, including physicians offices, labs and hospitals, are required by law to

More information

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis

More information

2016 Annual Tuberculosis Report For Fresno County

2016 Annual Tuberculosis Report For Fresno County 206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis

More information

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division

More information

TB: A Supplement to GP CLINICS

TB: A Supplement to GP CLINICS TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India

More information

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease Barbara J Seaworth MD Medical Director Heartland National TB Center Professor of Medicine University of Texas Health Center Tyler Barbara J Seaworth MD has

More information

Chapter 22. Pulmonary Infections

Chapter 22. Pulmonary Infections Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired

More information

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make: TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

MANAGEMENT OF TUBERCULOSIS IN NEONATES AND YOUNG INFANTS

MANAGEMENT OF TUBERCULOSIS IN NEONATES AND YOUNG INFANTS MANAGEMENT OF TUBERCULOSIS IN NEONATES AND YOUNG INFANTS A Bekker FIDSSA Conference, 2017 OUTLINE Case Perinatal TB Approach to the TB-exposed newborn MOM AND BABY S Born by NVD at peripheral hospital

More information

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening

More information

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening

More information

Pediatric TB Intensive San Antonio, Texas October 14, 2013

Pediatric TB Intensive San Antonio, Texas October 14, 2013 Pediatric TB Intensive San Antonio, Texas October 14, 2013 Treatment of Tuberculosis in Children Jeffrey R. Starke, M.D. Professor of Pediatrics October 14, 2013 Jeffrey R. Starke, M.D. has the following

More information

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014 Guidelines to Revisions to the School Mandate and Requirements 1) What are the tuberculosis (TB) screening requirements for school entrance in Santa Clara County? Students must undergo a TB risk assessment

More information

Anti Tuberculosis Medications: Side Effects & adverse Events

Anti Tuberculosis Medications: Side Effects & adverse Events Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,

More information

Diagnosis of tuberculosis in children H Simon Schaaf

Diagnosis of tuberculosis in children H Simon Schaaf Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence

More information

Pediatric Drug-Resistant TB in China

Pediatric Drug-Resistant TB in China Pediatric Drug-Resistant TB in China Shuihua Lu,Tao Li Shanghai Public Health Clinical Center Jan.18,2013 A MDR-TB CASE A four and a half years old boy, spent 4 yeas of his life in hospital. His childhood

More information

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t Selected Topics in LTBI June 2, 2015 Bijan Ghassemieh, MD Senior Fellow UW Division of Pulmonary/Critical Care Disclosures No disclosures or conflicts of interest to report Outline Special LTBI situations

More information

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How

More information

LTBI Videos-Treatment

LTBI Videos-Treatment LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of

More information

Tuberculosis Intensive

Tuberculosis Intensive Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests

More information

Pediatric Tuberculosis. Ann M. Loeffler, MD Pediatric TB Consultant Curry International Tuberculosis Center

Pediatric Tuberculosis. Ann M. Loeffler, MD Pediatric TB Consultant Curry International Tuberculosis Center Pediatric Tuberculosis Ann M. Loeffler, MD Pediatric TB Consultant Curry International Tuberculosis Center Introduction Basic situations in which children are evaluated Diagnosis and treatment of latent

More information

TB Intensive San Antonio, Texas

TB Intensive San Antonio, Texas TB Intensive San Antonio, Texas August 2-5, 2011 Pediatric TB Jeffrey Starke, MD August 5, 2011 Jeffrey Starke, MD has the following disclosures to make: Is on a data safety monitoring board for Hoffman

More information

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard

More information